A Phase 2B, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging, Multicentre Study to Investigate the Efficacy, Safety and Tolerability of the mGluR5 Negative Allosteric Modulator ADX10059 for the Prevention of Migraine
Phase of Trial: Phase II
Latest Information Update: 12 Aug 2016
At a glance
- Drugs ADX-10059 (Primary)
- Indications Migraine
- Focus Therapeutic Use
- 25 Dec 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 25 Dec 2009 Planned end date changed from 1 Sep 2009 to 1 Jan 2010 as reported by ClinicalTrials.gov.
- 15 Dec 2009 According to an Addex Pharmaceuticals media release, this trial has been prematurely terminated due to abnormalities in liver functions tests.